Comparative Effectiveness Without Head-to-Head Trials

James E. Signorovitch,Eric Q. Wu,Andrew P. Yu,Charles M. Gerrits,Evan Kantor,Yanjun Bao,Shiraz R. Gupta,Parvez M. Mulani
DOI: https://doi.org/10.2165/11538370-000000000-00000
2010-01-01
PharmacoEconomics
Abstract:The absence of head-to-head trials is a common challenge in comparative effectiveness research and health technology assessment. Indirect cross-trial treatment comparisons are possible, but can be biased by cross-trial differences in patient characteristics. Using only published aggregate data, adjustment for such biases may be impossible. Although individual patient data (IPD) would permit adjustment, they are rarely available for all trials. However, many researchers have the opportunity to access IPD for trials of one treatment, a new drug for example, but only aggregate data for trials of comparator treatments. We propose a method that leverages all available data in this setting by adjusting average patient characteristics in trials with IPD to match those reported for trials without IPD. Treatment outcomes, including continuous, categorical and censored time-to-event outcomes, can then be compared across balanced trial populations.
What problem does this paper attempt to address?